The Neurology Advisor Team spoke with Shilpa Reddy, MD, MMHC at AES 2025 in Atlanta, Georgia. Neurology Advisor: ā€œCan you describe your work in neuromodulation?ā€ ...
The Neurology Advisor Team spoke with Benjamin Deneen, PhD at AES 2025 in Atlanta, Georgia. Neurology Advisor: ā€œWhat is the bidirectional relationship between gliomas and neuronal activity?ā€ ...
The Neurology Advisor Team spoke with Alice Ballerini, PhD at AES 2025 in Atlanta, Georgia. Neurology Advisor: ā€œCan you describe your work in the epilepsy space?ā€ ...
Neurology Advisor: ā€œHow can AI optimize neuromodulation?ā€ ...
Dr Pavlova: ā€œIn terms of sleep apnea and epilepsy, the first barrier is to recognize it. There are signs that are very obvious, such as having a small chin, a large neck, or being overweight. These ...
The multidisciplinary epilepsy surgical conference review frequently alters SOZ interpretation and surgical plans for drug-resistant epilepsy.
Immediate neuro-rehabilitative treatment following moderate or severe TBI is associated with reduced risk of Alzheimer disease.
Impaired kidney function is associated with increased circulating levels of most Alzheimer disease blood biomarkers.
The FDA is facing even more leadership changes as drug regulator Dr Richard Pazdur prepares to retire at the end of the month.
The Food and Drug Administration has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease.
The FDA has approved Avance® (acellular nerve allograft-arwx) for the treatment of sensory nerve discontinuity.
Midazolam for refractory status epilepticus reduces 30-day mortality and complications versus propofol, though long-term outcomes are similar.